PureTech established the underlying programs and platforms that resulted in 29 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including three taken from inception at PureTech to FDA approval.
PureTech established the underlying programs and platforms that resulted in 28 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including two taken from inception at PureTech to FDA and EU regulatory clearances a third soon filing for FDA approval.

Programs1

Conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis
100% Equity
Phase 2 completed
See Our Program
Hematological malignancies, such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and locally advanced/metastatic solid tumors, including head and neck cancers
100% Equity
Phase 1/2
See Our Program
Neuropsychiatric conditions
35.6% Equity
Phase 2
See Our Program
Cobenfy™ (formerly known as KarXT) Now FDA Approved for the Treatment of Schizophrenia in Adults
Milestone Payments/ Royalties & up to $400M in milestone payments from agreement w/Royalty Pharma1
FDA Approved
See Our Program
Pioneering a new category of oral therapies based on defined bacterial consortia
35.8% Equity
Phase 3
See Our Program
Engineering hydrogels to enable the oral administration of peptide therapeutics (e.g., GLP-1 agonists)
73.8% Equity
Preclinical
See Our Program
A voice-based artificial intelligence platform to detect changes in health
34.9% Equity
Commercial Release
See Our Program

1 Programs refers to the Company’s current and future therapeutic candidates and technologies, including those that are being developed internally by PureTech and those being advanced within PureTech’s Founded Entities. Relevant ownership interests were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2024, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. PureTech controls Gallop Oncology, Inc. Vor ownership was calculated on a beneficial ownership basis in accordance with SEC rules as of March 13, 2025. 

PureTech Level Cash, Cash Equivalents & Short-Term Investments

$339.1M
PureTech Level Cash, Cash Equivalents and Short-Term Investments as of March 31, 20253

3 PureTech level cash, cash equivalents and short-term investments excludes cash and cash equivalents at non-wholly owned subsidiary of $0.4m. PureTech level cash, cash equivalents and short-term investments is a non-IFRS measure.

Developing breakthrough medicines at PureTech